SELLAS Life Sciences Group, Inc. - 10-Q Filing

SELLAS Life Sciences reports Q3 2026 financial results with 203.8 million shares of common stock outstanding as of November 11, 2026.

SEC EDGAR · November 12, 2026, 21:00 UTC

Tickers: $SLS

More Regulatory news

Ascend Wellness Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:10 UTC
ON SEMICONDUCTOR CORP - 8-K Filing SEC EDGAR · November 12, 2026, 21:10 UTC
Equillium, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:10 UTC
Exyn Technologies, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:10 UTC
Sanara MedTech Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:10 UTC
Invesco Galaxy Ethereum ETF - 8-K Filing SEC EDGAR · November 12, 2026, 21:10 UTC
PLIANT THERAPEUTICS, INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:09 UTC
Arcadia Biosciences, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:09 UTC
US Foods Holding Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 21:09 UTC
MARZETTI CO - 8-K Filing SEC EDGAR · November 12, 2026, 21:10 UTC